Brief: Celltrion Inc Receives S.Korea Approval For Vegzelma, A Biosimilar Anticancer Drug
29/09/2022 24:56
Celltrion Inc 068270.KS :
* CELLTRION INC: RECEIVES S.KOREA APPROVAL FOR VEGZELMA, A
BIOSIMILAR ANTICANCER DRUG
Source text for Eikon: ID:
Further company coverage: 068270.KS
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares